The abstract is read at the publisher; the summary is JClub's.
In 37 early-stage lung cancer patients from Guangzhou, South China, 6PPD and PTPD-Q dominated blood while PTPD and N-phenyl-N'-cyclohexyl-p-phenylenediamine-quinone dominated urine.
- Why it matters: Limited patient data leave uncertainty about how substituted p-phenylenediamines/PPD-quinones relate to tumor marker and clinical indicators in lung cancer.
- What they did: The study quantified 15 PPDs/PPD-Qs in paired whole blood and urine, then tested associations with 10 typical medical indicators, including tumor markers, before and after false discovery rate correction.
- The result: Renal excretion was robust but clearance differed by monomer, with 6PPD-quinone showing higher clearance than 6PPD (mean 180 vs 8 mL day−1 kg−1); tumor marker α-fetoprotein and neuron-specific enolase showed relatively stronger pre-correction links that were not significant after correction.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.